Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Dulaglutide may reduce stroke in T2D

Roshini Claire Anthony
31 Jan 2020

The GLP-1 receptor agonist* dulaglutide may reduce the incidence of stroke, particularly ischaemic stroke, in individuals with type 2 diabetes (T2D) and cardiovascular (CV) risk factors, according to findings of an exploratory analysis of the REWIND** trial.

The multinational trial involved 9,901 individuals aged 50 years with T2D (HbA1c 9.5 percent), BMI 23 kg/m2, and cardiovascular (CV) risk factors on stable doses of 2 oral glucose-lowering drugs (with or without basal insulin). They were randomized to receive either subcutaneous dulaglutide (1.5 mg/week) or placebo. About 93 percent of patients had hypertension at baseline, 9.1 percent had a history of stroke or transient ischaemic attack (TIA), and 6.4 percent had a history of atrial fibrillation (AF). Participants continued using their guideline-directed medical therapies during the trial.

Over the median 5.4-year follow-up period, the incidence of fatal or non-fatal stroke was significantly reduced among patients who received dulaglutide compared with placebo recipients (3.2 percent vs 4.1 percent; hazard ratio [HR], 0.76, 95 percent confidence interval [CI], 0.62–0.94; p=0.010). [Lancet Diabetes Endocrinol 2020;doi;10.1016/S2213-8587(19)30423-1]

The reduction in stroke incidence with dulaglutide was specific to ischaemic stroke (HR, 0.75, 95 percent CI, 0.59–0.94; p=0.012), with no apparent effect on the incidence of haemorrhagic stroke (HR, 1.05, 95 percent CI, 0.55–1.99; p=0.89), unknown type of stroke (HR, 0.82, 95 percent CI, 0.40–1.66; p=0.58), or TIA (HR, 0.79, 95 percent CI, 0.52–1.20; p=0.27).

There was also a reduction in non-fatal stroke with dulaglutide vs placebo (HR, 0.76, 95 percent CI, 0.61–0.95; p=0.017) as well as disabling stroke*** (HR, 0.74, 95 percent CI, 0.56–0.99; p=0.042), but no impact on fatal stroke (HR, 0.78, 95 percent CI, 0.47–1.30; p=0.34), though the number of events for this outcome was small (n=26 vs 33). There was also a significant reduction in the composite of non-fatal stroke or all-cause death with dulaglutide vs placebo (HR, 0.88, 95 percent CI, 0.79–0.98; p=0.017).

The reduction in stroke with dulaglutide was comparable across multiple subgroups, including age, sex, systolic blood pressure, AF, HbA1c, history of cardiovascular or cerebrovascular disease, or use of renin-angiotensin system medications or statins.

Additional exploratory analyses suggested that the effect of dulaglutide on stroke reduction may be attributed to several factors including the reduction in systolic blood pressure or HbA1c, which accounted for up to 14 and 54 percent of the effect, respectively. “[However], much of the effect of dulaglutide on stroke could be due to mechanisms that are independent of these two risk factors,” noted the researchers.

“[This study] meaningfully supports the consideration of GLP-1 receptor agonists for stroke prevention in people with T2D at increased CV risk,” said Dr Vanita Aroda from Brigham and Women’s Hospital, Boston, Massachusetts, US, in an editorial. [Lancet Diabetes Endocrinol 2020;doi:10.1016/S2213-8587(19)30427-9]

“[G]iven the frequency of stroke in people with diabetes, the severity of its associated morbidity, and the paucity of preventive therapies, the findings of this study suggest that GLP-1 receptor agonists should be considered when developing future stroke prevention guidelines for people with diabetes,” the researchers added.

 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.